Back to search

Article

Cellular Mechanisms Associated with Sub-Optimal Immune Responses to SARS-CoV-2 Bivalent Booster Vaccination in Patients with Multiple Myeloma

2023-08-29

Abstract excerpt

Background: The real-world impact of bivalent vaccines for wild type (WA1) and Omicron variant (BA5) is largely unknown in immunocompromised patients with Multiple Myeloma (MM). We characterize the humoral and cellular immune responses in patients with MM before and after receiving the bivalent booster, including neutralizing assays to identify patterns associated with continuing vulnerability to current variants...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a6e027ec-19ac-5f04-b7c7-b84589cd95a7
DOI
10.2139/ssrn.4550619
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Cellular Mechanisms Associated with Sub-Optimal Immune Responses to SARS-CoV-2 Bivalent Booster Vaccination in Patients with Multiple MyelomaDOI 10.2139/ssrn.4550619
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patientsSemantic proximity
Impact of Omicron variant on the response to SARS-CoV-2 mRNA Vaccination in multiple myelomaSemantic proximity
Loss of Anti-Spike Antibodies Following mRNA Vaccination for COVID-19 Among Patients with Multiple MyelomaSemantic proximity
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunitySemantic proximity
Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patientsSemantic proximity
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunitySemantic proximity
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myelomaSemantic proximity
Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccinationSemantic proximity
Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple MyelomaSemantic proximity
Impaired Neutralisation of SARS-CoV-2 Delta Variant in Vaccinated Patients With B Cell Chronic Lymphocytic LeukaemiaSemantic proximity
Rational engineering of sdAb-based CAR T cells targeting BCMA enhances antitumor efficacy and persistence in Multiple MyelomaSemantic proximity
Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myelomaSemantic proximity
Select a neighboring publication to make it the new centre.